Polypoidal Choroidal Vasculopathy: Prognosis
The prognosis for polypoidal choroidal vasculopathy (PCV) is guarded, with approximately 80% of patients experiencing disease reactivation despite initial treatment response, though 21-51% can achieve long-term remission after initial therapy. 1
Visual Outcomes
Long-term visual prognosis depends critically on several key factors:
Early polypoidal regression is the strongest predictor of favorable outcomes. Eyes achieving complete polypoidal regression within 3 months of initial treatment demonstrate significantly better visual acuity at both 1 year and 3 years compared to those with persistent polyps 2
Recurrence patterns heavily influence final vision. Patients maintaining 5-year remission after initial combination therapy (PDT + anti-VEGF) show substantial visual improvement (mean logMAR BCVA improving from 0.39 to 0.17), while those with recurrence maintain baseline vision without improvement (0.58 to 0.60 logMAR) 3
Baseline characteristics matter significantly. Worse final visual acuity correlates with: presence of recurrence, larger greatest linear dimension, and cluster polyp configuration (versus single polyps) 4
Recurrence Risk Stratification
Favorable prognostic factors for lower recurrence risk include: 4
- Younger age at onset
- Higher choroidal vascularity index (CVI)
- Presence of choroidal vascular hyperpermeability (CVH)
- Female sex 3
- Better baseline visual acuity 3
- Lower ARMS2 A69S risk allele frequency 3
Critical caveat: Even among patients achieving 5-year remission, 11.8% still experience recurrence between years 5-7, necessitating continued long-term monitoring 3
Treatment Response and Anatomical Outcomes
Polyp regression rates vary dramatically by treatment modality: 5
- PDT monotherapy: 89% complete regression at 12 months
- PDT + anti-VEGF combination: 78% complete regression
- Anti-VEGF monotherapy: 42% complete regression
However, anti-VEGF monotherapy achieves the lowest recurrence rate (14%), creating a clinical paradox where initial anatomical response doesn't predict long-term stability 5
Combination therapy (PDT + anti-VEGF) demonstrates superior outcomes: 5
- Highest dry macula rate: 91%
- Best visual improvement
- Optimal balance of anatomical and functional outcomes
Long-Term Disease Course
The natural trajectory shows: 1
- 21.7-51.5% achieve long-term remission after initial treatment
- 81.3% eventually experience lesion reactivation
- Chronic treatment burden is substantial for most patients
Complications affecting long-term prognosis include: 6
- Recurrent hemorrhage
- Subretinal fibrosis
- Geographic atrophy
- Persistent or recurrent exudation
Prognostic Imaging Biomarkers
On OCT/OCTA, favorable characteristics for early complete polypoidal regression include: 2
- Smaller hyperreflective lesion area within pigment epithelial detachment (PED)
- More flow signals visible within hyperreflective lesions
The number of persistent polypoidal lesions at 3 months post-treatment directly correlates with visual acuity at both 1 and 3 years (r=0.498, p=0.006 and r=0.397, p=0.033 respectively) 2
Clinical Context from Guidelines
While the provided guidelines focus primarily on central serous chorioretinopathy, they consistently note that PCV (described as aneurysmal type 1 neovascularization) represents a distinct entity associated with poorer visual prognosis 7. Up to two-thirds of CSC patients who develop macular neovascularization have a polypoidal component, and ICGA remains essential for identifying these lesions 8, 7.
Treatment recommendations from guidelines emphasize: 8
- Combination of full-dose PDT with anti-VEGF (ranibizumab or aflibercept) based on EVEREST II and PLANET trials
- 50% polypoidal lesion closure with full-fluence PDT monotherapy versus 25% with anti-VEGF monotherapy
Bottom Line for Clinical Practice
Prognosis is highly variable and depends on achieving early complete polypoidal regression. Patients with younger onset, higher CVI, presence of CVH, and complete polyp regression by 3 months have the best long-term outcomes. However, even optimal responders require indefinite monitoring as late reactivation occurs in approximately 12% after 5 years of remission. The majority (80%) will require chronic treatment, making PCV a lifelong disease requiring sustained management rather than a condition amenable to cure.